KemPharm (NASDAQ:KMPH) has received an average recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $10.75.
Several research firms have recently weighed in on KMPH. Canaccord Genuity set a $11.00 price objective on shares of KemPharm and gave the company a “buy” rating in a report on Friday, February 23rd. ValuEngine cut shares of KemPharm from a “hold” rating to a “sell” rating in a report on Friday, February 23rd. Royal Bank of Canada set a $9.00 price objective on shares of KemPharm and gave the company a “buy” rating in a report on Tuesday, January 16th. Oppenheimer set a $13.00 price objective on shares of KemPharm and gave the company a “buy” rating in a report on Sunday, February 25th. Finally, Zacks Investment Research cut shares of KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th.
KemPharm stock traded down $0.42 during trading hours on Wednesday, hitting $6.28. The stock had a trading volume of 127,961 shares, compared to its average volume of 138,750. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. The stock has a market capitalization of $101.20, a PE ratio of -2.12 and a beta of -0.34. KemPharm has a 12-month low of $2.45 and a 12-month high of $8.40.
KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.04). equities research analysts forecast that KemPharm will post -2.59 EPS for the current fiscal year.
An institutional investor recently raised its position in KemPharm stock. Victory Capital Management Inc. boosted its holdings in shares of KemPharm (NASDAQ:KMPH) by 26.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 162,077 shares of the specialty pharmaceutical company’s stock after buying an additional 34,114 shares during the quarter. Victory Capital Management Inc. owned approximately 1.11% of KemPharm worth $656,000 at the end of the most recent quarter. 36.56% of the stock is currently owned by institutional investors.
KemPharm Company Profile
KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.